TY - JOUR
AR - IJSCR-2020-3-105
TI - Successful Management of COVID-19 Pneumonia Following Live-Related Kidney Transplant in a 74-Year-Old Recipient
AU - Sameh , Mayaleh 
AU - John , Black
AU - Islam , Eldiasty
AU - Baher , Elshikh
AU - Krishna , Thayagaraj
AU - Anna , Rizello
AU - Taher , Doughman
AU - Mohamed , Morsy
AU - Atul , Bagul
JO - International Journal of Surgical Case Reports
PY - 2020
DA - Fri 14, Aug 2020
SN - 2674-4171
DO - http://dx.doi.org/10.31487/j.IJSCR.2020.03.05
UR - https://www.sciencerepository.org/successful-management-of-covid-19-pneumonia-following-live-related-kidney_IJSCR-2020-3-105 
KW - COVID-19, corona virus, kidney transplantation, live-related kidney transplantation, ESKD
AB - Background: COVID-19 infection is the most recent worrying viral pandemic worldwide. Little is
understood regarding the course of illness and subsequent immediate and long-term complications. Despite
numerous ongoing trials, there is still no agreed mode of treatment for this viral illness. Live-donor renal
transplantation is the gold standard treatment for end-stage renal disease. Those patients undergoing renal
transplantation are deemed particularly high risk for contracting COVID-19 secondary to the effects of
immunosuppression. This case report discusses management of COVID-19 infection in a 74-year-old male,
who underwent a live-related kidney transplant.
Case Presentation: A 74-year-old Caucasian male patient, developed renal failure due to diabetic
nephropathy since 2012. The patient was transplanted in 2013 with a graft from a deceased donor, but
unfortunately this kidney failed in 2014, aetiology unknown. Haemodialysis was recommenced until he
received a second kidney transplant from a live-related donor in March 2020. Unfortunately, postoperative
recovery was complicated with COVID-19 infection. The clinical signs and symptoms, along with details
surrounding presentation are discussed. This includes the rationale behind the management of such highrisk immunosuppressed patients with COVID-19 infection.
Conclusion: There is still no consensus about the best modality for treating COVID-19 infection in
recipients of solid organ transplantation. From our experience, temporarily stopping the anti-proliferative
immunosuppressant (e.g. Mycophenolate mofetil) during the acute illness seemed to enhance recovery of
the acute phase of the disease.